Multimutated Herpes Simplex Virus G207 Is a Potent Inhibitor of Angiogenesis

This publication has 48 references indexed in Scilit:

• Utilizing Tumor Hypoxia to Enhance Oncolytic Viral Therapy in Colorectal Metastases
  Annals of Surgery, 2004
• Clinical translation of angiogenesis inhibitors
  Nature Reviews Cancer, 2002
• Functional Interaction between Fluorodeoxyuridine-Induced Cellular Alterations and Replication of a Ribonucleotide Reductase-Negative Herpes Simplex Virus
  Journal of Virology, 2001
• Corticosteroid Administration Does Not Affect Viral Oncolytic Activity, but Inhibits Antitumor Immunity in ReplicationCompetent Herpes Simplex Virus Tumor Therapy
  Human Gene Therapy, 1999
• Treatment of Human Breast Cancer in a Brain Metastatic Model by G207, a Replication-Competent Multimutated Herpes Simplex Virus 1
  Human Gene Therapy, 1998
• Factors that contribute to the transneuronal spread of herpes simplex virus
  Journal of Neuroscience Research, 1997
• Enhancement of Gene Therapy Specificity for Diffuse Colon Carcinoma Liver Metastases with Recombinant Herpes Simplex Virus
  Annals of Surgery, 1996
• What Is the Evidence That Tumors Are Angiogenesis Dependent?
  JNCI Journal of the National Cancer Institute, 1990
• Tumor Angiogenesis: Therapeutic Implications
  New England Journal of Medicine, 1971
• Effect of hydroxyurea on ribonucleotide reductase
  Biochemical and Biophysical Research Communications, 1968